Compare AbbVie Inc (ABBV) vs STMicroelectronics NV (STM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs STMicroelectronics NV — how do they compare? AbbVie Inc trades at $253.8 (market cap $449.91B), while STMicroelectronics NV trades at $67.48 (market cap $59.25B). The key difference: AbbVie Inc is far larger — about 7.6× STMicroelectronics NV's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | STM | |
|---|---|---|
Market Cap | $449.91B | $59.25B |
Sector | Health | Financials |
52-Week High | $261.07 | $79.91 |
52-Week Low | $184.85 | $21.20 |
Enterprise Value | $513.38B | $57.46B |
Dividend Yield | 2.72% | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
STM trades at $67.28, down 1.57% today, with a neutral technical signal and mixed earnings history. The company shows strong cash flow from operations at $2.15B in 2025 and maintains a solid balance sheet with $6.18B cash. Recent news highlights growth in AI, automotive, and industrial segments, including new product launches like the VL53L9 LiDAR module. Analyst consensus is a Buy with a $72.33 price target, indicating potential upside from current levels.
Outlook is cautiously optimistic given STM's strategic positioning in high-growth semiconductor markets, but high valuation ratios (P/E 446.19) and recent earnings misses pose risks. Revenue decline from $17.3B in 2023 to $11.8B in 2025 requires monitoring, though cost control and innovation in edge AI and automotive chips offer long-term opportunities amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
